查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1961065

全球腫瘤臨床試驗市場：依階段類型、研究設計和地區劃分 - 市場規模、產業動態、機會分析和預測（2026-2035 年）

Global Oncology Clinical Trials Market: Analysis By Phase Type, Study Design, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 260 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球腫瘤臨床試驗市場正經歷顯著成長，反映出人們越來越重視開發新型有效的癌症療法。該市場在 2025 年的價值約為 149.5 億美元，預計將大幅擴張，到 2035 年達到 256.1 億美元。這一成長意味著在 2026 年至 2035 年的預測期內，複合年增長率 (CAGR) 為 5.53%，凸顯了腫瘤藥物研發的持續動能和投資。

推動這一強勁成長的關鍵因素有很多。其中一個關鍵驅動因素是全球癌症發生率的上升，這推動了對創新療法的需求，並加速了臨床研究的進程。隨著人口老化以及環境和生活方式因素的變化導致癌症發病率上升，發現並儘早引入新療法的需求變得越來越重要。

市場趨勢展望

腫瘤臨床試驗市場競爭激烈且充滿活力，主要特徵是大型製藥公司之間的激烈競爭，以及積極的整合和策略聯盟的形成。這種競爭環境反映了開發突破性癌症療法的高風險，以及藥物成功獲準帶來的豐厚經濟回報。阿斯特捷利康、默克、羅氏和諾華等領先公司已確立了其在該領域的主導地位。

到2025年，這些領先公司將共同控制約35%的腫瘤臨床試驗項目，這表明它們將在塑造癌症治療的未來方面發揮重要作用。它們的主導地位不僅源自於雄厚的財力和科學專長，也源自於其在藥物開發和市場滲透方面的策略性方法。

  • 例如，阿斯特捷利康已在快速發展的抗體藥物偶聯物（ADC）領域確立了領先地位。 這項成功主要歸功於其突破性的抗體偶聯藥物 (ADC) Enhart，該藥物已在多種癌症類型中展現出顯著的臨床效益。 核心成長驅動因素 全球癌症發生率的不斷上升構成了一項緊迫的醫療保健挑戰，大大推動了對新型有效療法加速研發的需求。由於人口老化、生活方式改變和環境因素的影響，全球癌症發病率持續上升，因此發現創新療法並將其推向市場的緊迫性日益增強。日益加重的癌症負擔不僅影響患者的治療結果，也給醫療保健系統帶來了巨大的壓力，要求其提供及時有效的干預措施。 新興機遇 人工智慧驅動的技術正在迅速改變腫瘤臨床試驗的關鍵環節，尤其是在患者招募、方案設計和數據管理方面。這些先進技術為解決長期存在的挑戰和效率低下問題提供了新的機遇，這些問題歷來阻礙臨床研究的進展和成功。人工智慧使試驗申辦方和研究人員能夠簡化複雜流程、提高準確性並優化資源分配，最終提升整體效率。
  • 優化障礙
  • 腫瘤臨床試驗市場面臨的最大挑戰仍然是病患招募的持續困難。儘管招募足夠的受試者對於確保試驗的有效性和成功至關重要，但歷史上只有一小部分（不到 5%）成年癌症患者參與臨床研究。如此低的入組率是藥物研發過程中的一個主要瓶頸，減緩了研發進度，並限制了收集關於新型療法的全面數據的能力。

      目錄

      第一章：摘要整理：全球腫瘤臨床試驗市場

      第二章：報告概述

      • 研究框架
        • 研究目標
        • 市場定義
        • 市場區隔
      • 研究方法
        • 市場規模估算
        • 質性研究
        • 量化研究
        • 依地區劃分的原始調查受訪者細分
        • 資料三角驗證
        • 研究假設

      第三章：全球腫瘤臨床試驗市場概述

      • 產業價值鏈分析
        • 藥物發現與臨床前研究研發
        • 臨床試驗設計與監理審批
        • 臨床試驗實施與病患招募
        • 臨床試驗物資供應與物流
        • 資料分析與監理申報
        • 商業化
      • 行業展望
        • 不斷擴充的腫瘤藥物研發管線
        • 全球癌症發生率上升
        • 外包給合約研究組織 (CRO) 的趨勢日益增長
        • 精準醫療的普及應用
        • 腫瘤臨床試驗支持的監管
      • PESTLE 分析
      • 波特五力分析
      • 供應商議價能力
      • 買方議價能力
      • 替代品威脅
      • 新進入者威脅
      • 競爭強度
    • 市場成長與展望
      • 市場收入估計與預測（2020-2035 年）
      • 價格分析（以階段類型劃分）
    • 市場吸引力分析
      • 以階段類型劃分
    • 可操作的洞見（分析師建議）

    第四章 競爭格局概覽

    • 市場集中度
    • 公司佔有率分析（基於價值，2025 年）
    • 競爭格局分析與基準分析

    第五章：全球腫瘤臨床試驗市場分析

    • 市場動態與趨勢
      • 成長驅動因素
      • 限制因素
      • 機遇
      • 關鍵因素趨勢
    • 市場規模及預測（2020-2035）
      • 以階段類型劃分
      • 依研究設計劃分
      • 依地區劃分

    第六章：北美腫瘤臨床試驗市場分析

    第七章：歐洲腫瘤臨床試驗市場分析

    第八章：亞太腫瘤臨床試驗市場分析

    第九章：中東和非洲腫瘤臨床試驗市場分析

    第十章：南美洲腫瘤臨床試驗市場分析

    第11章 企業簡介

    • AbbVie Inc.
    • AstraZeneca PLC
    • BeiGene Ltd.
    • Bristol Myers Squibb
    • Charles River Laboratories
    • Clovis Oncology
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • IQVIA
    • ICON plc
    • Johnson &Johnson
    • Labcorp Drug Development
    • Medpace Holdings
    • Merck &Co., Inc.
    • Novartis AG
    • Parexel International
    • Pfizer Inc.
    • Syneos Health
    • Takeda Pharmaceutical
    • Thermo Fisher Scientific
    • Wuxi Clinical CRO
    • Other Prominent Players

    第12章 附錄

簡介目錄
Product Code: AA12251628

The global oncology clinical trials market is witnessing substantial growth, reflecting the increasing focus on developing new and effective cancer treatments. Valued at approximately USD 14.95 billion in 2025, the market is projected to expand significantly, reaching an estimated valuation of USD 25.61 billion by 2035. This growth corresponds to a compound annual growth rate (CAGR) of 5.53% over the forecast period from 2026 to 2035, highlighting the sustained momentum and investment flowing into oncology drug development.

Several key factors are driving this robust expansion. One of the primary contributors is the rising incidence of cancer worldwide, which has prompted greater demand for innovative therapies and accelerated clinical research efforts. As cancer rates climb due to aging populations and changing environmental and lifestyle factors, the urgency to discover and bring forward new treatment options intensifies.

Noteworthy Market Developments

The oncology clinical trials market is highly competitive and dynamic, marked by intense rivalry among leading pharmaceutical companies as well as a trend towards aggressive consolidation and the formation of strategic partnerships. This competitive environment reflects the high stakes involved in developing groundbreaking cancer therapies and the significant financial rewards that come with successful drug approvals. Major players in this arena, such as AstraZeneca, Merck & Co., Roche, and Novartis, have established themselves as dominant forces.

By 2025, these top-tier companies have collectively secured control over approximately 35% of the total oncology clinical trial pipeline, underscoring their influential role in shaping the future of cancer treatment. Their dominance is not only a result of their financial resources and scientific expertise but also a reflection of their strategic approaches to drug development and market penetration.

  • AstraZeneca, for example, has carved out a leadership position in the rapidly evolving Antibody-Drug Conjugate (ADC) segment of oncology. This success is largely attributed to Enhertu, a breakthrough ADC that has demonstrated significant clinical benefits across multiple cancer types.
  • Core Growth Drivers
  • The increasing global prevalence of cancer has become a pressing healthcare challenge, significantly fueling the demand for faster development of new and effective treatments. As cancer incidence rates continue to rise worldwide due to factors such as aging populations, lifestyle changes, and environmental influences, the urgency to discover and bring innovative therapies to market has intensified. This growing burden of cancer not only impacts patient outcomes but also places immense pressure on healthcare systems to provide timely and effective interventions.
  • Emerging Opportunity Trends
  • AI-driven technologies are rapidly transforming key aspects of oncology clinical trials, particularly in the areas of patient recruitment, protocol design, and data management. These advanced technologies offer new opportunities to address longstanding challenges and inefficiencies that have traditionally hindered the pace and success of clinical research. By leveraging artificial intelligence, trial sponsors and researchers can now streamline complex processes, enhance precision, and optimize resource allocation, ultimately contributing to improved overall efficiency.
  • Barriers to Optimization
  • Patient recruitment continues to be the most significant challenge facing the oncology clinical trials market. Despite the critical importance of enrolling sufficient participants to ensure the validity and success of trials, historically, only a small fraction of adult cancer patients-less than 5%-have participated in clinical research. This low enrollment rate poses a major bottleneck in the drug development process, slowing progress and limiting the ability to gather comprehensive data on new treatments.

Detailed Market Segmentation

By phase type, the Phase III studies emerge as the most financially significant segment, representing over 48.89% of the total revenue share. This considerable dominance is largely due to the scale and complexity inherent in Phase III trials, which serve as the pivotal step before a new therapy can receive regulatory approval. Unlike earlier phases, Phase III trials typically involve enrolling a much larger patient population, averaging around 479 participants per study. These trials are conducted across hundreds of sites worldwide, reflecting their global scope and the need to gather extensive data from diverse patient groups to ensure the treatment's safety and efficacy.

By study design, the interventional studies segment holds a commanding position, accounting for more than 71% of the total revenue share within the clinical trials market. This dominance is largely attributable to the intricate and resource-intensive nature of investigational product (IP) dosing intrinsic to interventional studies. Unlike observational studies, which typically involve monitoring and data collection with minimal intervention, interventional trials require meticulous planning, administration, and management of therapeutic agents. These complexities drive higher costs and greater logistical challenges, including the need for specialized personnel, stringent regulatory compliance, and robust patient monitoring protocols, all of which contribute significantly to the revenue generated by this segment.

Segment Breakdown

By Phase Type

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Study Design

  • Interventional Studies
  • Observational Studies
  • Expanded Access Studies

By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • South America

Geography Breakdown

  • North America stands at the forefront of the global oncology clinical trials market, accounting for a dominant share of over 58% of radiation oncology studies as of early 2024. This leadership position underscores the region's significant influence in some of the most lucrative and cutting-edge segments within oncology, particularly radiopharmaceuticals and advanced cellular therapies. The strong presence of world-class research institutions, substantial funding, and a robust regulatory framework contribute to this dominance, fostering an environment conducive to innovation and rapid development of new cancer treatments.
  • Data from recent years highlights the explosive growth in clinical research activities across North America. The total number of registered clinical studies in the region has surged dramatically, increasing from 477,200 in 2023 to an impressive 520,874 by late 2024. Within this vast research landscape, oncology interventions represent a substantial portion, with 68,453 trials dedicated to testing new cancer therapies and approaches. This significant volume of oncology trials reflects both the urgency of addressing cancer as a major health challenge and the region's capacity to conduct complex, large-scale studies.

Leading Market Participants

  • AbbVie Inc.
  • AstraZeneca PLC
  • BeiGene Ltd.
  • Bristol Myers Squibb
  • Charles River Laboratories
  • Clovis Oncology
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • IQVIA
  • ICON plc
  • Johnson & Johnson
  • Labcorp Drug Development
  • Medpace Holdings
  • Merck & Co., Inc.
  • Novartis AG
  • Parexel International
  • Pfizer Inc.
  • Syneos Health
  • Takeda Pharmaceutical
  • Thermo Fisher Scientific
  • Wuxi Clinical CRO
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Oncology Clinical Trials Market

Chapter 2. Report Description

  • 2.1. Research Framework
    • 2.1.1. Research Objective
    • 2.1.2. Market Definitions
    • 2.1.3. Market Segmentation
  • 2.2. Research Methodology
    • 2.2.1. Market Size Estimation
    • 2.2.2. Qualitative Research
      • 2.2.2.1. Primary & Secondary Sources
    • 2.2.3. Quantitative Research
      • 2.2.3.1. Primary & Secondary Sources
    • 2.2.4. Breakdown of Primary Research Respondents, By Region
    • 2.2.5. Data Triangulation
    • 2.2.6. Assumption for Study

Chapter 3. Global Oncology Clinical Trials Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Drug Discovery & Preclinical Development
    • 3.1.2. Clinical Trial Planning & Regulatory Approval
    • 3.1.3. Clinical Trial Execution & Patient Recruitment
    • 3.1.4. Clinical Trial Supply & Logistics
    • 3.1.5. Data Analysis & Regulatory Submission
    • 3.1.6. Commercialization
  • 3.2. Industry Outlook
    • 3.2.1. Growing Oncology Drug Pipeline
    • 3.2.2. Increasing Cancer Incidence Globally
    • 3.2.3. Rising Outsourcing to CROs
    • 3.2.4. Increasing Adoption of Precision Medicine
    • 3.2.5. Regulatory Support for Oncology Trials
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Pricing Analysis, By Phase Type
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. By Phase Type
  • 3.7. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking

Chapter 5. Global Oncology Clinical Trials Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Phase Type
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Phase I
        • 5.2.1.1.2. Phase II
        • 5.2.1.1.3. Phase III
        • 5.2.1.1.4. Phase IV
    • 5.2.2. By Study Design
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Interventional Studies
        • 5.2.2.1.2. Observational Studies
        • 5.2.2.1.3. Expanded Access Studies
    • 5.2.3. By Region
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. North America
          • 5.2.3.1.1.1. The U.S.
          • 5.2.3.1.1.2. Canada
          • 5.2.3.1.1.3. Mexico
        • 5.2.3.1.2. Europe
          • 5.2.3.1.2.1. Western Europe
            • 5.2.3.1.2.1.1. The UK
            • 5.2.3.1.2.1.2. Germany
            • 5.2.3.1.2.1.3. France
            • 5.2.3.1.2.1.4. Italy
            • 5.2.3.1.2.1.5. Spain
            • 5.2.3.1.2.1.6. Rest of Western Europe
          • 5.2.3.1.2.2. Eastern Europe
            • 5.2.3.1.2.2.1. Poland
            • 5.2.3.1.2.2.2. Russia
            • 5.2.3.1.2.2.3. Rest of Eastern Europe
        • 5.2.3.1.3. Asia Pacific
          • 5.2.3.1.3.1. China
          • 5.2.3.1.3.2. India
          • 5.2.3.1.3.3. Japan
          • 5.2.3.1.3.4. South Korea
          • 5.2.3.1.3.5. Australia & New Zealand
          • 5.2.3.1.3.6. ASEAN
            • 5.2.3.1.3.6.1. Indonesia
            • 5.2.3.1.3.6.2. Malaysia
            • 5.2.3.1.3.6.3. Thailand
            • 5.2.3.1.3.6.4. Singapore
            • 5.2.3.1.3.6.5. Rest of ASEAN
          • 5.2.3.1.3.7. Rest of Asia Pacific
        • 5.2.3.1.4. Middle East & Africa
          • 5.2.3.1.4.1. UAE
          • 5.2.3.1.4.2. Saudi Arabia
          • 5.2.3.1.4.3. South Africa
          • 5.2.3.1.4.4. Rest of MEA
        • 5.2.3.1.5. South America
          • 5.2.3.1.5.1. Argentina
          • 5.2.3.1.5.2. Brazil
          • 5.2.3.1.5.3. Rest of South America

Chapter 6. North America Oncology Clinical Trials Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Phase Type
    • 6.2.2. By Study Design
    • 6.2.3. By Country

Chapter 7. Europe Oncology Clinical Trials Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Phase Type
    • 7.2.2. By Study Design
    • 7.2.3. By Country

Chapter 8. Asia Pacific Oncology Clinical Trials Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Phase Type
    • 8.2.2. By Study Design
    • 8.2.3. By Country

Chapter 9. Middle East & Africa Oncology Clinical Trials Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Phase Type
    • 9.2.2. By Study Design
    • 9.2.3. By Country

Chapter 10. South America Oncology Clinical Trials Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Phase Type
    • 10.2.2. By Study Design
    • 10.2.3. By Country

Chapter 11. Company Profile (Company Overview, Company Timeline, Organization Structure, Key Product landscape, Financial Matrix, Key Customers/Sectors, Key Competitors, SWOT Analysis, Contact Address, and Business Strategy Outlook)

  • 11.1. AbbVie Inc.
  • 11.2. AstraZeneca PLC
  • 11.3. BeiGene Ltd.
  • 11.4. Bristol Myers Squibb
  • 11.5. Charles River Laboratories
  • 11.6. Clovis Oncology
  • 11.7. Eli Lilly and Company
  • 11.8. F. Hoffmann-La Roche Ltd
  • 11.9. IQVIA
  • 11.10. ICON plc
  • 11.11. Johnson & Johnson
  • 11.12. Labcorp Drug Development
  • 11.13. Medpace Holdings
  • 11.14. Merck & Co., Inc.
  • 11.15. Novartis AG
  • 11.16. Parexel International
  • 11.17. Pfizer Inc.
  • 11.18. Syneos Health
  • 11.19. Takeda Pharmaceutical
  • 11.20. Thermo Fisher Scientific
  • 11.21. Wuxi Clinical CRO
  • 11.22. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators